Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Neoadjuvant pertuzumab: the exception that proves the rule?

Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.